公司资料
Genprex 股价、新闻与催化剂
- 股票代码:
- GNPX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.63 USD (+2.73%)
收盘价
最后更新: 2026年10月2日
7.78M USD
市值
股价为何变动
截至 2026年10月2日，GNPX 上涨 2.73%，收于 $2.63。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Gene Therapy Company
Genprex develops gene therapies for cancer and diabetes. Its platform uses non-viral nanoparticles to deliver tumor-suppressor genes systemically and separate gene constructs intended to restore insulin production.
REQORSA Tumor-Suppressor Therapy
REQORSA, or quaratusugene ozeplasmid, delivers the TUSC2 tumor-suppressor gene in a lipid nanoparticle. The therapy is designed to restore anticancer signaling and make tumors more responsive to targeted therapy or immunotherapy.
Acclaim Lung Cancer Programs
Acclaim-1 combines REQORSA with osimertinib in EGFR-mutated non-small cell lung cancer after progression on Tagrisso. Acclaim-3 evaluates REQORSA with atezolizumab in extensive-stage small cell lung cancer.
Biomarker-Guided Development
Genprex is working with Roche to validate biomarkers that may identify patients most likely to benefit from REQORSA combinations. A clearer biomarker strategy could guide enrollment and interpretation of later clinical studies.
Diabetes Gene Therapy Portfolio
The company also owns preclinical diabetes programs designed to convert pancreatic cells into insulin-producing cells. These assets broaden the platform beyond oncology but remain earlier in development.
未来催化剂
- Completion of the REQORSA biomarker-validation work with Roche around the end of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。